Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with or without AZD6244 in wild-type BRAF advanced melanoma
2009-018153-23Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of selumetinib in melanoma (2 arms), sponsored by University of Oxford. Primary endpoint: Progression-free survival. Started Jul 2010; status: completed.
02
Drugs
selumetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-018153-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018153-23.